Tests BMS-986528 in adults with hard-to-treat rheumatoid arthritis
Tests the safety of BMS-986528 in adults with hard-to-treat rheumatoid arthritis.
Plain-language title generated from the registry record
Registry title: A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis
Key facts
- Where
- Berlin, Cologne, Herne, Munich, and Sendenhorst, GermanySee the 5 sites
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07412704, who can take part
Where in Germany
- Charite Research Organisation GmbHBerlin, GermanyTaking people
- Universitaetsklinikum Koeln AöRCologne, GermanyTaking people
- St. Elisabeth Gruppe GmbH Katholische Kliniken Rhein-RuhrHerne, GermanyTaking people
- LMU Klinikum Muenchen AöRMunich, GermanyTaking people
- St. Josef Stift GmbHSendenhorst, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT07412704EU 2025-520666-22-00
- Record updated
- 23 October 2026
- Original description
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the preliminary evidence of disease-modifying effect of BMS-986528 in participants with refractory, difficult-to-treat rheumatoid arthritis (RA).Read full original descriptionShow less
A Phase 1/2a, Open-label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of BMS-986528 in Participants With Refractory Rheumatoid Arthritis
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the preliminary evidence of disease-modifying effect of BMS-986528 in participants with refractory, difficult-to-treat rheumatoid arthritis (RA).
Inclusion: Adult participants with rheumatoid arthritis (RA) who meet definition of difficult-to-treat.
Exclusion: Juvenile arthritis or onset of inflammatory arthritis before age 18; Seronegative RA participants in whom polymyalgia rheumatica has not been ruled out; Active fibromyalgia with pain symptoms or signs that would interfere with joint assessment; Other protocol-defined Inclusion/Exclusion criteria apply.